Henning Zeidler

Publications (300) View all

• Article: Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC).

  Denis Poddubnyy, Hildrun Haibel, Joachim Listing, Elisabeth Märker-Hermann, Henning Zeidler, Jürgen Braun, Joachim Sieper, Martin Rudwaleit
  Annals of the rheumatic diseases 04/2013; · 8.11 Impact Factor
• Article: Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.

  Ariel Beresniak, Christoph Baerwald, Henning Zeidler, Klaus Krüger, Aljoscha S Neubauer, Danielle Dupont, Sonja Merkesdal
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVES: The treatment of active rheumatoid arthritis (RA) usually requires different therapeutic options used sequentially in case of an insufficient response (IR) to previous agents. Since there is a lack of clinical trials comparing biologic treatment sequences, simulation models might add to the understanding of optimal treatment sequences and their cost-effectiveness. The objective of this study was to assess the cost-effectiveness of different biologic treatment strategies in patients with an IR to anti-TNF agents, based on levels of disease activity from the German public payer's perspective. METHODS: A cost-effectiveness sequential model was developed in accordance with local RA treatment strategies, using DAS28 scores as dichotomous effectiveness endpoints: achieving remission/no remission (RS/no RS) or a state of low disease activity (LDAS/no LDAS). Costs were estimated using resource utilisation data obtained from a large observational German cohort. Advanced simulations were conducted to assess the cost-effectiveness over 2 years of four sequential biologic strategies composed of up to 3 biologic agents, namely anti-TNF agents, abatacept or rituximab, in patients with moderate-to-severe active RA and an IR to at least one anti-TNF agent. RESULTS: Over two years, the biological sequence including abatacept after an IR to one anti-TNF agent appeared the most effective and cost-effective versus (vs.) use after two anti-TNF agents (€633 vs. €1,067/day in LDAS and €1,222 vs. €3,592/day in remission), and vs a similar sequence using rituximab (€633 vs. €728/day in LDAS and €1,222 vs. €1,812/day in remission). The sequence using a 3rd anti-TNF agent was less effective and cost-effective than the same sequence using abatacept (€2,000 vs. €1,067/day in LDAS and €6,623 vs. €3,592/day in remission). All differences were statistically significant (p<0.01). CONCLUSIONS: The results suggest that in patients with an IR to at least one anti-TNF agent, biologic sequences including abatacept appear more efficacious and cost-effective than similar sequences including rituximab or only cycled anti-TNF agents.
  Clinical and experimental rheumatology 03/2013; · 2.15 Impact Factor
• Article: Great artists with rheumatoid arthritis: what did their disease and coping teach? Part I. Pierre-auguste renoir and alexej von jawlensky.

  Henning Zeidler
  [show abstract] [hide abstract]
  ABSTRACT: The famous artists Pierre-Auguste Renoir (1841-1919) and Alexej von Jawlensky (1864-1941) had rheumatoid arthritis (RA). Both represent an outstanding example of successful coping with RA in former times when treatment was very limited, and these individuals took advantage of creative disease management. The most popular French impressionist painter Renoir used his creativity to develop his own exercises and assistive equipments for painting despite his disability. Thus, Renoir exemplifies an artistic life altered by RA over more than 25 years that he dedicated entirely to his art and the depiction of beauty and happiness testified by his own words: "The pain passes, but the beauty remains." Jawlensky, a Russian from origin, was one of the most important expressionist painter active in Germany and the first painter in the 20th century who created extensive series of paintings especially of human faces. From Jawlensky, we learned that his rapidly progressing, late-onset RA induced depression, disability, financial pressure, and social retreat. But the resulting artistic sublimation contributed to the change in his paintings, which we owe the more than 1000 series of the very unique, small-format "Meditations."For those interested in art, new insight will be opened into the life and work of the artists and increase the appreciation for their contribution to modern art.
  Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 09/2012; 18(7):376-81. · 1.19 Impact Factor
• Article: Investigating the barriers to effective management of musculoskeletal pain: an international survey

  Anthony Woolf, Alison Carr, Jurgen Frolich, Mario Guslandi, Beat Michel, Henning Zeidler, on behalf of the Arthritis Action Group
  [show abstract] [hide abstract]
  ABSTRACT: An international study was performed to investigate the discrepancy between physician and population perception of the management of musculoskeletal pain (MP). One thousand, one hundred and fifty-four people with MP and 604 primary care physicians randomly selected from six countries (UK, Germany, Italy, France, Australia and Mexico) were interviewed by telephone. The interviews were based on structured questionnaires that captured: the management of pain, knowledge about the condition, sources of information, information communicated within the consultation, and patient roles in pain management. People with MP are confused about the different treatment options available (up to 63% out of N = 1,154) to them and their relative benefits and risks (33–51%). Doctors are the most valued and appropriate source of information (by up to 80% of people, N = 1,154) but are difficult to access. When people do have a clinical consultation, there may be a disparity between the information doctors convey and patient recall of the information provided. For example, most doctors tell patients the number of tablets they will need to take to achieve optimal pain relief, but only 34–63% of people with MP recall being given this information. Lack of information may partially explain why so few people (7–36%) return to their doctor when their prescribed medication is ineffective. This survey identified lack of information as a potential barrier to effective treatment. Physicians’ perceptions that people with MP are not able to appraise all the information and may prefer a passive role in their care need to be challenged if patients are to be participants in the management of their condition.
  Clinical Rheumatology 04/2012; 27(12):1535-1542. · 2.00 Impact Factor
• Article: The need to better classify and diagnose early and very early rheumatoid arthritis.

  Henning Zeidler
  [show abstract] [hide abstract]
  ABSTRACT: Early rheumatoid arthritis (RA) and very early RA are major targets of research and clinical practice. Remission has become a realistic goal in the management of RA, particularly in early disease. The 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) RA classification criteria, the EULAR treatment recommendations for RA, and the EULAR recommendations for the management of early arthritis focus on early disease and translate the knowledge related to early RA into classification and management. Nevertheless, there is a need for further improvement and progress. Results from 6 recent studies are summarized, evaluating the performance of the 2010 ACR/EULAR RA classification criteria. The data show a significant risk of misclassification, and highlight that overdiagnosis and underdiagnosis may become important issues if the criteria recommend synthetic and biological disease-modifying antirheumatic drugs. Therefore, some considerations are presented on how the current problems and limitations could be overcome in clinical practice and future research. A consensus is needed to better define the early phase of RA and differentiate from other early arthritis. The possible effect of misclassification on spontaneous and drug-induced remission of early and very early RA awaits further elucidation. Such research will eventually lead to more reliable diagnostic and classification criteria for new-onset RA.
  The Journal of Rheumatology 12/2011; 39(2):212-7. · 3.69 Impact Factor